Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00943943
Recruitment Status : Completed
First Posted : July 22, 2009
Last Update Posted : March 29, 2017
Genzyme, a Sanofi Company
National Cancer Institute (NCI)
Georgia Institute of Technology
Information provided by (Responsible Party):
M.D. Anderson Cancer Center

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : March 23, 2017
  Actual Study Completion Date : March 23, 2017